OBJECTIVE: To develop a more age-appropriate spirometric definition of chronic obstructive pulmonary disease (COPD) among older persons. METHODS: Using data from the Third National Health and Nutrition Examination Survey (NHANES III), we developed a two-part spirometric definition of COPD in older persons, aged 65-80 years, that 1) determines a cut-point for the ratio of forced expiratory volume in 1 s to forced vital capacity (FEV1/FVC) based on mortality risk; and 2) among persons below this critical FEV1/FVC threshold, determines cut-points for the FEV1, expressed as a standardized residual percentile (SR-tile) and based on the prevalence of respiratory symptoms and mortality risk. Measurements included spirometry, health questionnaires, and mortality (National Death Index). RESULTS: There were 2480 older participants with a mean age of 71.7 years; 1372 (55.4%) had a smoking history, 1097 (44.2%) had respiratory symptoms and, over the course of 12-years, 868 (35.0%) had died. Among participants with an FEV1/FVC<.70 and FEV1<5th SR-tile, representing 7.7% of the cohort, the risk of death was doubled (adjusted hazard ratio, 2.01; 95% confidence interval [CI], 1.60-2.54). Among participants with an FEV1/FVC<.70 and FEV1<10th SR-tile, representing 13.4% of the cohort, the prevalence of respiratory symptoms was elevated (adjusted odds ratio, 2.44; CI, 1.79-3.33). CONCLUSION: In a large, nationally representative sample of community-living older persons, defining COPD based on an FEV1/FVC<.70, with FEV1 cut-points at the 10th and 5th SR-tiles, identifies individuals with an increased prevalence of respiratory symptoms and an increased risk of death, respectively.
OBJECTIVE: To develop a more age-appropriate spirometric definition of chronic obstructive pulmonary disease (COPD) among older persons. METHODS: Using data from the Third National Health and Nutrition Examination Survey (NHANES III), we developed a two-part spirometric definition of COPD in older persons, aged 65-80 years, that 1) determines a cut-point for the ratio of forced expiratory volume in 1 s to forced vital capacity (FEV1/FVC) based on mortality risk; and 2) among persons below this critical FEV1/FVC threshold, determines cut-points for the FEV1, expressed as a standardized residual percentile (SR-tile) and based on the prevalence of respiratory symptoms and mortality risk. Measurements included spirometry, health questionnaires, and mortality (National Death Index). RESULTS: There were 2480 older participants with a mean age of 71.7 years; 1372 (55.4%) had a smoking history, 1097 (44.2%) had respiratory symptoms and, over the course of 12-years, 868 (35.0%) had died. Among participants with an FEV1/FVC<.70 and FEV1<5th SR-tile, representing 7.7% of the cohort, the risk of death was doubled (adjusted hazard ratio, 2.01; 95% confidence interval [CI], 1.60-2.54). Among participants with an FEV1/FVC<.70 and FEV1<10th SR-tile, representing 13.4% of the cohort, the prevalence of respiratory symptoms was elevated (adjusted odds ratio, 2.44; CI, 1.79-3.33). CONCLUSION: In a large, nationally representative sample of community-living older persons, defining COPD based on an FEV1/FVC<.70, with FEV1 cut-points at the 10th and 5th SR-tiles, identifies individuals with an increased prevalence of respiratory symptoms and an increased risk of death, respectively.
Authors: Sanja Stanojevic; Angie Wade; Janet Stocks; John Hankinson; Allan L Coates; Huiqi Pan; Mark Rosenthal; Mary Corey; Patrick Lebecque; Tim J Cole Journal: Am J Respir Crit Care Med Date: 2007-11-15 Impact factor: 21.405
Authors: Amir Qaseem; Vincenza Snow; Paul Shekelle; Katherine Sherif; Timothy J Wilt; Steven Weinberger; Douglas K Owens Journal: Ann Intern Med Date: 2007-11-06 Impact factor: 25.391
Authors: Klaus F Rabe; Suzanne Hurd; Antonio Anzueto; Peter J Barnes; Sonia A Buist; Peter Calverley; Yoshinosuke Fukuchi; Christine Jenkins; Roberto Rodriguez-Roisin; Chris van Weel; Jan Zielinski Journal: Am J Respir Crit Care Med Date: 2007-05-16 Impact factor: 21.405
Authors: Carlos A Vaz Fragoso; Thomas M Gill; Gail McAvay; Henry Klar Yaggi; Peter H Van Ness; John Concato Journal: J Investig Med Date: 2011-10 Impact factor: 2.895
Authors: Carlos A Vaz Fragoso; Thomas M Gill; Gail McAvay; Peter H Van Ness; H Klar Yaggi; John Concato Journal: Respir Care Date: 2011-05-20 Impact factor: 2.258
Authors: Carlos A Vaz Fragoso; John Concato; Gail McAvay; Peter H Van Ness; Carolyn L Rochester; H Klar Yaggi; Thomas M Gill Journal: Respir Med Date: 2010-03-03 Impact factor: 3.415
Authors: Carlos A Vaz Fragoso; John Concato; Gail McAvay; H Klar Yaggi; Peter H Van Ness; Thomas M Gill Journal: J Am Geriatr Soc Date: 2011-09-13 Impact factor: 5.562
Authors: Carlos A Vaz Fragoso; John Concato; Gail McAvay; Peter H Van Ness; Carolyn L Rochester; H Klar Yaggi; Thomas M Gill Journal: Am J Respir Crit Care Med Date: 2009-12-17 Impact factor: 21.405
Authors: Surya P Bhatt; Jessica C Sieren; Mark T Dransfield; George R Washko; John D Newell; Douglas S Stinson; Gideon K D Zamba; Eric A Hoffman Journal: Thorax Date: 2013-03-23 Impact factor: 9.139
Authors: Kjell Toren; Linus Schiöler; Anne Lindberg; Anders Andersson; Annelie F Behndig; Göran Bergström; Anders Blomberg; Kenneth Caidahl; Jan Engvall; Maria Eriksson; Viktor Hamrefors; Christer Janson; David Kylhammar; Eva Lindberg; Anders Lindén; Andrei Malinovschi; Hans Lennart Persson; Martin Sandelin; Jonas Eriksson Ström; Hanan A Tanash; Jenny Vikgren; Carl Johan Östgren; Per Wollmer; C Magnus Sköld Journal: BMJ Open Respir Res Date: 2020-08